Functional TCR T cell screening using single-cell droplet microfluidics
Abstract
Adoptive T cell transfer, in particular TCR T cell therapy, holds great promise for cancer immunotherapy with encouraging clinical results. However, finding the right TCR T cell clone is a tedious, time-consuming, and costly process. Thus, there is a critical need for single cell technologies to conduct fast and multiplexed functional analyses followed by recovery of the clone of interest. Here, we use droplet microfluidics for functional screening and real-time monitoring of single TCR T cell activation upon recognition of target tumor cells. Notably, our platform includes a tracking system for each clone as well as a sorting procedure with 100% specificity validated by downstream single cell reverse-transcription PCR and sequencing of TCR chains. Our TCR screening prototype will facilitate immunotherapeutic screening and development of T cell therapies.
Additional Information
© 2018 The Royal Society of Chemistry. The article was received on 07 Aug 2018, accepted on 26 Oct 2018 and first published on 06 Nov 2018. This article is part of the themed collections: Lab on a Chip Emerging Investigators and Droplet-based single-cell sequencing. The authors would like to thank Chih Chun Yu for his help in finishing the TCR T cell activation experiments in droplets and assistance in droplet sorting, and Stephanie Wong for her help in single cell PCR work. The authors are also grateful to Cassandra Kiyomi Davis for her support in culturing the cells and performing cell viability test from droplets. This work is supported by the NIH (1DP2CA195763 and R21CA219225), and Amberstone Biosciences LLC: No. AB-208317. Author contributions: Conceptualization, A. I. S., G. L., G. W. and W. Z.; methodology, A. I. S., G. L., L. K., C. R., X. C. and G. W.; investigation, A. I. S, G. L., L. K., C. R., and J. K. W.; analysis, A. I. S.; writing: original draft, A. I. S. and W. Z.; editing, A. I. S., G. L., L. K., X. C., J. K. W., D. B., G. W. and W. Z.; supervision, A. I. S., D. B., G. W. and W. Z. Conflicts of interest: Weian Zhao is a co-founder of Amberstone Biosciences LLC that develops immunotherapeutics.Attached Files
Accepted Version - nihms-996455.pdf
Supplemental Material - c8lc00818c1.pdf
Supplemental Material - c8lc00818c2.pdf
Supplemental Material - c8lc00818c3.avi
Supplemental Material - c8lc00818c4.avi
Supplemental Material - c8lc00818c5.avi
Supplemental Material - c8lc00818c6.avi
Files
Name | Size | Download all |
---|---|---|
md5:f33e8cbec84c639ecfe54cf198d3ea2a
|
114.8 kB | Preview Download |
md5:49c4a60db41504eba947994039af08c4
|
7.2 MB | Download |
md5:03d957398080b6ad9b9bab31a24a458f
|
5.3 MB | Download |
md5:7527b0128ab38b7d3dfa16b3b6055d58
|
1.5 MB | Download |
md5:cc7fed594efd38198fb2be5554835237
|
2.7 MB | Preview Download |
md5:0eb6bedb799454dd61ea27fd0d4b6dbe
|
296.4 kB | Preview Download |
md5:e2bd73667be04cfb08329ac41b569a62
|
10.3 MB | Download |
Additional details
- PMCID
- PMC6279597
- Eprint ID
- 90667
- DOI
- 10.1039/c8lc00818c
- Resolver ID
- CaltechAUTHORS:20181106-104559775
- NIH
- 1DP2CA195763
- NIH
- R21CA219225
- Amberstone Biosciences LLC
- AB-208317
- Created
-
2018-11-06Created from EPrint's datestamp field
- Updated
-
2022-02-16Created from EPrint's last_modified field